Protocol to Obtain Blood Samples for Leukemia Research

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2016 by Dartmouth-Hitchcock Medical Center
Sponsor:
Information provided by (Responsible Party):
Dartmouth-Hitchcock Medical Center
ClinicalTrials.gov Identifier:
NCT00889031
First received: April 24, 2009
Last updated: May 4, 2016
Last verified: May 2016
  Purpose
The purpose of this study is to collect a blood sample in patients with Chronic Lymphocytic Leukemia (CLL).

Condition Intervention
Chronic Lymphocytic Leukemia
Other: No Intervention

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Protocol to Obtain Blood Samples for Leukemia Research

Resource links provided by NLM:


Further study details as provided by Dartmouth-Hitchcock Medical Center:

Primary Outcome Measures:
  • To determine the frequency with which CLL cells incubated ex vivo with vincristine undergo rapid interphase apoptosis. [ Time Frame: 2 Years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To determine whether suppression or inhibition of BCL2 family members can acutely sensitize CLL cells to vincristine. [ Time Frame: 2 Years ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA
10cc of peripheral blood.

Estimated Enrollment: 50
Study Start Date: April 2009
Estimated Study Completion Date: April 2020
Estimated Primary Completion Date: April 2020 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
No Treatment Other: No Intervention
Patients with Chronic Lymphocytic Leukemia (CLL)

Detailed Description:
The blood sample will be used in the laboratory to perform studies focusing on Chronic Lymphocytic Leukemia (CLL).
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients at Dartmouth-Hitchcock Medical Center's Norris Cotton Cancer Center
Criteria

Inclusion Criteria:

  • Patients undergoing routine blood draws as part of their ongoing follow-up for Chronic Lymphocytic Leukemia (CLL) at the Norris Cotton Cancer Center of DHMC.

Exclusion Criteria:

  • Patients who have received cytotoxic drug, oral or intravenous steroid or targeted antibody therapy for CLL or other disease process within the past 6 months are excluded. Use of intravenous immunoglobulin (IVIg) is not a reason for exclusion.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00889031

Contacts
Contact: Research Nurse 800-639-6918 cancer.research.nurse@dartmouth.edu
Contact: Nancy Rollings 603-650-5135 Nancy.J.Rollings@Hitchcock.org

Locations
United States, New Hampshire
Dartmouth-Hitchcock Medical Center Recruiting
Lebanon, New Hampshire, United States, 03756
Contact: Research Nurse    800-639-6918    cancer.research.nurse@dartmouth.edu   
Contact: Nancy Rollings    603-650-5135    Nancy.J.Rollings@Hitchcock.org   
Principal Investigator: Christopher H Lowrey         
Sponsors and Collaborators
Dartmouth-Hitchcock Medical Center
Investigators
Principal Investigator: Christopher H Lowrey, MD Dartmouth-Hitchcock Medical Center
  More Information

Publications:
Responsible Party: Dartmouth-Hitchcock Medical Center
ClinicalTrials.gov Identifier: NCT00889031     History of Changes
Other Study ID Numbers: D0905 
Study First Received: April 24, 2009
Last Updated: May 4, 2016
Health Authority: United States: Institutional Review Board

Keywords provided by Dartmouth-Hitchcock Medical Center:
CLL

Additional relevant MeSH terms:
Leukemia
Leukemia, Lymphoid
Leukemia, Lymphocytic, Chronic, B-Cell
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia, B-Cell

ClinicalTrials.gov processed this record on July 21, 2016